Recently small molecules that inhibit the BET family of epigenetic reader proteins and impact Myc gene expression have shown excellent pre-clinical efficacy in Myc-dependent tumor models [21, 22, 23] and are currently in clinical trials. This evidence concerns the gene MYC and neoplasm.